Abexinostat Shows Promise for B Cell Lymphoma

Abexinostat, a novel pan-histone deacetylase inhibitor, is emerging as a promising therapeutic agent for patients with relapsed or refractory B cell non-Hodgkin lymphoma (NHL), a group of aggressive blood cancers with limited treatment options. Recently, a Phase 1 clinical trial conducted in Chinese patients has shed light on the safety profile, pharmacokinetic properties, and therapeutic potential of abexinostat, revealing encouraging outcomes that could pave the way for larger-scale studies and eventual clinical adoption.

Histone deacetylase inhibitors (HDACis) have garnered significant attention over the past decade for their ability to alter gene expression by modulating chromatin structure. By inhibiting HDAC enzymes, these agents promote the accumulation of acetylated histones, resulting in transcriptional activation of tumor suppressor genes and induction of programmed cell death pathways in malignant cells. Abexinostat is distinguished by its pan-HDAC inhibitory activity, targeting multiple HDAC isoforms, which may enhance its antitumor efficacy across various lymphoma subtypes.

In the recently published Phase 1 trial executed between April 2020 and November 2023, twelve Chinese patients diagnosed with relapsed or refractory B cell NHL were enrolled. The cohort comprised individuals with follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). The study’s primary goal was to evaluate safety and pharmacokinetic parameters of escalating oral doses of abexinostat administered twice daily in a regimen described as “one week on, one week off.” This intermittent schedule was designed to maximize antitumor activity while mitigating potential toxicities.

.adsslot_GWe1faFUn7{ width:728px !important; height:90px !important; }
@media (max-width:1199px) { .adsslot_GWe1faFUn7{ width:468px !important; height:60px !important; } }
@media (max-width:767px) { .adsslot_GWe1faFUn7{ width:320px !important; height:50px !important; } }

ADVERTISEMENT

Patients received abexinostat at dose levels of 40 mg, 60 mg, and 80 mg twice daily, separated by a 4-hour interval, over seven days followed by a seven-day drug-free interval. Importantly, a single dose of abexinostat was administered three days prior to the initiation of the continuous dosing period to assess immediate pharmacokinetics and identify any dose-limiting toxicities. This strategic dosing approach enabled careful monitoring of tolerability while capturing pharmacologic data critical for optimizing future dosing regimens.

The safety evaluation revealed a highly tolerable profile of abexinostat across all dose levels. Notably, no dose-limiting toxicities were observed, even at the highest dose of 80 mg twice daily, which was subsequently declared the recommended Phase 2 dose (RP2D). Adverse events were predominantly mild to moderate, with the most common Grade 3 adverse events including thrombocytopenia and hypertriglyceridemia occurring in a minority of patients. These findings suggested that abexinostat could be administered safely at doses likely to produce meaningful biological effects.

Pharmacokinetic analyses underscored the drug’s favorable absorption and elimination characteristics. Median time to maximum plasma concentration (Tmax) ranged from 0.5 to 1.0 hours post-dose, indicating rapid systemic availability. The terminal half-life (T1/2) varied between 2.56 to 8.31 hours, supporting the twice-daily dosing strategy. Furthermore, plasma concentrations demonstrated dose-proportional kinetics, a desirable pharmacological attribute that facilitates predictable exposure-response relationships.

Efficacy signals from this early-phase trial were equally promising. Within the evaluable patient population, the objective response rate (ORR) was 40%, comprising one complete response and three partial responses. Particularly compelling was the 50% ORR observed among follicular lymphoma patients, a group traditionally characterized by chronic disease courses but often limited treatment responsiveness after multiple relapses. Median progression-free survival for follicular lymphoma patients reached 8.38 months, while duration of response extended to 7.82 months, durations encouraging for such a treatment-refractory population.

While overall survival data remain immature given the study’s timeframe, the absence of deaths during the observation period reinforces the favorable risk-benefit profile of abexinostat. The trial’s pioneering status as the first evaluation of this agent in a Chinese NHL population also expands understanding of HDAC inhibitor pharmacology across diverse ethnic groups, addressing an important gap in global oncology research.

The investigators concluded that the “one week on, one week off” oral dosing schedule is a rational approach based on pharmacokinetic observations, balancing steady drug exposure with recovery periods to reduce cumulative toxicity. This intermittent dosage regimen aligns with contemporary trends in targeted cancer therapies that seek to maintain efficacy while optimizing patient quality of life.

Beyond mere tolerability and pharmacokinetics, the demonstration of clear antitumor activity in heavily pretreated patients positions abexinostat as a candidate for further clinical development. Larger Phase 2 and 3 trials are warranted to confirm these early efficacy signals, delineate patient subgroups most likely to benefit, and potentially explore combination strategies with immunotherapies or standard chemotherapy agents.

This study contributes to the evolving landscape of precision oncology, where molecularly targeted agents such as HDAC inhibitors challenge traditional cytotoxic chemotherapy paradigms. In relapsed or refractory lymphomas, where therapeutic resistance diminishes options, new drugs with novel mechanisms of action are critical to improving survival and quality of life.

Moreover, the research underscores the importance of integrating pharmacokinetic assessments early in drug development programs. Understanding how a candidate drug behaves systemically in various patient populations informs safer and more effective dosing protocols, ultimately accelerating the pathway from bench to bedside.

As abexinostat advances through clinical stages, attention will also turn to biomarker identification to predict response and monitor treatment effects. Delineating epigenetic signatures or immune milieu alterations induced by HDAC inhibition could refine patient selection and personalize therapy.

The promising results from this Phase 1 trial offer hope to patients confronting the challenges of relapsed or refractory B cell NHL. In a disease domain in urgent need of innovation, abexinostat’s favorable safety and preliminary efficacy data propel it forward as a potential new weapon in the oncologist’s armamentarium.

Looking ahead, collaborative global efforts and comprehensive clinical investigations remain essential to validate these findings. Success in these endeavors could herald a new chapter in lymphoma treatment, harnessing epigenetic modulation to achieve durable remissions and improve patient outcomes worldwide.

Subject of Research: Abexinostat as a novel pan-histone deacetylase inhibitor in relapsed/refractory B cell non-Hodgkin lymphoma

Article Title: Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study

Article References: Gui, L., Xie, Z., Qin, Y. et al. Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study. BMC Cancer 25, 967 (2025). https://doi.org/10.1186/s12885-025-14370-y

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14370-y

Tags: Abexinostat for B cell lymphomaantitumor efficacy of HDACisdiffuse large B-cell lymphoma researchfollicular lymphoma treatment optionsgene expression modulation in lymphomahistone deacetylase inhibitors in cancerpan-histone deacetylase inhibitorpharmacokinetics of HDAC inhibitorsPhase 1 clinical trial Chinarelapsed refractory non-Hodgkin lymphomasafety profile of abexinostattherapeutic potential of abexinostat